PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Prazosin hydrochloride - Benign prostatic hyperplasia

PAD Profile : Prazosin hydrochloride - Benign prostatic hyperplasia

Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Hypovase, Minipress

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Indoramin & Prazosin will be considered BLACK on traffic light system because these two drugs were not considered as part of the NICE clinical guideline. (CG97). Patients receiving these drugs on the NHS prior to this recommendation must be reviewed by their NHS consultant (or initiating clinician) but should be able to continue treatment until the patient and their NHS consultant (or initiating clinician) consider it appropriate to stop. Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option - Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules) - Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK) Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically) Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More